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Abstract 36 
Purpose To compare and examine the storage stability of compounded bevacizumab 37 
in polycarbonate (PC) and polypropylene (PP) syringes over a 6-month period. PC 38 
syringes have been used in a recent clinical study and bevacizumab stability has not 39 
been reported for this type of syringe. 40 
Methods Repackaged bevacizumab was obtained from Moorfields Pharmaceuticals in 41 
polycarbonate (PC) and polypropylene (PP) syringes. Bevacizumab from the stored 42 
syringes was analysed at monthly time points for a 6-month period and compared 43 
with bevacizumab from a freshly opened vial at each time point. SDS-PAGE 44 
electrophoresis and size-exclusion chromatography (SEC) was used to observe 45 
aggregation and degradation. Dynamic light scattering (DLS) provided information 46 
about the hydrodynamic size and particle size distribution of bevacizumab in solution. 47 
VEGF binding and the active concentration of bevacizumab was determined by 48 
surface plasmon resonance (SPR) using Biacore.  49 
Results SDS-PAGE and SEC analysis did not show any changes in the presence of 50 
higher molecular species (HMWS) or degradation products in PC and PP syringes 51 
from T0 to T6 compared to bevacizumab sampled from a freshly opened vial. The 52 
hydrodynamic diameter of bevacizumab in the PC syringe after six months of storage 53 
was not significantly different to bevacizumab taken from a freshly opened vial. 54 
Using SPR, the VEGF binding activity of bevacizumab in the PC syringe was 55 
comparable with bevacizumab taken from a freshly opened vial.  56 
Conclusion No significant difference over a 6-month period was observed in the 57 
quality of bevacizumab repackaged into prefilled PC polycarbonate and PP 58 
polypropylene syringes when compared to bevacizumab that is supplied from the vial.  59 
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Introduction 66 
Two recent multi-center randomised controlled clinical trials compared the use of 67 
ranibizumab (Lucentis, Genentech) and bevacizumab (Avastin, Genentech) to treat 68 
wet age-related macular degeneration (AMD).1-4 These trials (IVAN and CATT) 69 
found there is no difference in visual acuity outcome during one and two year 70 
treatment periods respectively.2, 3 Both ranibizumab and bevacizumab were developed 71 
to bind to vascular endothelial growth factor (VEGF) as a means to inhibit blood 72 
vessel growth.5 Ranibizumab is a humanised antibody fragment (Fab) that is licensed 73 
for intravitreal injection to treat AMD and other retinal conditions.6-10  74 
Bevacizumab is a humanised monoclonal full-length antibody that is licensed 75 
for administeration by intravenous infusion to treat cancer (metastatic colorectal, 76 
NSCLC, renal cell cancer, glioblastoma).11, 12 It is not licensed for intravitreal 77 
injection to treat retinal diseases. Bevacizumab is normally provided as a solution in a 78 
glass vial containing 400 mg of the antibody at a concentration of 25 mg/mL. For 79 
ocular use, bevacizumab is often transferred under aseptic conditions into ready-to-80 
use 1.0 ml syringes for intravitreal injection by compounding pharmacies for local 81 
distribution. A shelf life of up to 3 months13, 14 is often specified. To avoid the risks 82 
and costs of compounding there have been reports of ‘multiple use’ from a vial of 83 
bevacizumab to treat patients consecutively. However there is the risk of infection if 84 
the vial is punctured multiple times and an increased incidence of endophthalmitis has 85 
been reported.15  86 
The National Institute for Clinical Health and Care Excellence (NICE) 87 
considers the compounding of bevacizumab into syringes followed by storage prior to 88 
ophthalmic use to be unlicensed, rather than off-license use of bevacizumab.16 In spite 89 
of head-to-head trials indicating that ranibizumab and bevacizumab are clinically 90 
statistically equivalent, some safety results from the CATT study indicate there may 91 
be a greater burden of side effects for bevacizumab compared to ranibizumab.  92 
The cost of compounded bevacizumab per intravitreal dose is approximately 93 
5-9% of the cost of a dose of ranibizumab.17 Moderate to severe disabilities in our 94 
ageing population, of which diminishing visual function is one, are projected to 95 
increase by 32-54% in the UK by 2022.17 Ranibizumab and bevacizumab are used for 96 
other major ophthalmic diseases affecting older patients including diabetic 97 
retinopathy and retinal vein occlusion, while AMD is the main cause of blindness for 98 
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these older patients.18 Unfortunately costs have generally become a constraining 99 
factor for the use of expensive medicines in many parts of the world. It is not 100 
unreasonable to expect that intravitreal use of bevacizumab will continue in many 101 
parts of the world, especially in resource limited regions and especially for older 102 
patients whose overall health and social care costs are already high and are expected 103 
to increase.17, 18  104 
The reported incidence of IOP spike19, 20 or endophthalmitis that may be 105 
associated with bevacizumab injections21-24 is thought to be related to the presence of 106 
particulates or protein aggregates.20, 25 The presence of silicon oil contamination and 107 
the type of syringe used for repackaged bevacizumab has also been reported to be 108 
associated with an increase in protein aggregates or particulate count.14 As with any 109 
protein therapeutictherapeutic antibodies, exposure to light, storage temperature, 110 
product handling, and syringe components can cause protein misfolding, denaturation 111 
and aggregation. These changes in protein structure can decrease protein activity and 112 
may result in immunological responses.26  113 
Ranibizumab has recently become available in ready-to-use glass syringes27, 28 114 
but the cost of this medicine has yet to drop. Unfortunately the compounding and 115 
subsequent storage of bevacizumab in plastic syringes have not been approved by 116 
regulatory agencies. One important factor to consider is the different types of syringe 117 
that are used for bevacizumab. Reports have been published about bevacizumab being 118 
compounded into polypropylene (PP) syringes13, 14, 29, 30 and the effects of storage 119 
conditions20, 31 on the stability and efficacy of bevacizumab. Polycarbonate (PC) 120 
syringes have also been used, and were used in the IVAN trial.20, 32 There does not 121 
however appear to be a report about the stability of bevacizumab when repackaged in 122 
polycarbonate syringes (Table 1).  123 
TABLE 1 124 
In this study, we examined the stability of compounded bevacizumab in both 125 
polycarbonate (PC) and polypropylene (PP) syringes. The PC syringe had a luer-lock 126 
to secure the needle. The more commonly used PP syringe had a slip-lock to hold the 127 
needle. The bevacizumab filled syringes were then stored at 5 ± 3 °C. The stored 128 
bevacizumab filled syringes were evaluated monthly over a 6-month period by SDS-129 
PAGE gel electrophoresis, size-exclusion chromatography (SEC), dynamic light 130 
scattering (DLS), and surface plasmon resonance (SPR). 131 
132 
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Materials and Methods 133 
Materials 134 
Bevacizumab (Avastin, Genentech, 400 mg) solution from a vial (16 mL) was 135 
aseptically fractionated into 1.0 mL sterile syringes at Moorfields Pharmaceuticals a 136 
day before starting the first time point. The volume of the bevacizumab solution 137 
transferred to each syringe was 0.13 mL. Two different syringes (as shown in table 2) 138 
were evaluated, polycarbonate (PPPC) with a luer-lock barrel and (ii) polypropylene 139 
(PP) with a slip-lock barrel (Table 2). A fresh vial of bevacizumab was used for the 140 
control data obtained at each time point. The filled syringes and vials were stored at 141 
50C ± 30C and the temperature was monitored and recorded at regular intervals at 142 
Moorfields Pharmaceuticals. At each sampling time point, syringes were shipped to 143 
the UCL School of Pharmacy where stability studies were conducted within 24 hour 144 
of receipt. 145 
TABLE 2 146 
Methods 147 
Study design 148 
The bevacizumab solution in PC and PP syringes was evaluated for its 149 
physicochemical stability over a 6-month period at monthly time points and compared 150 
with bevacizumab solution obtained from freshly opened vials. Only one vial was 151 
used per time point and data generated during 8 hour period on the day that vial was 152 
open. The time points are designated as T0 (first time point after fractionation 153 
procedure), T3 and T6 representing three and six-month storage period. 154 
Gel-electrophoresis SDS-PAGE 155 
Novex bis-tris 4-12% precast gels (Invitrogen, UK) were used for PAGE analysis. 156 
Solutions were first prepared by taking the bevacizumab solution from a syringe (0.05 157 
mL) and the same volume of bevacizumab solution from the vial (0.05 mL) and 158 
adding each to Phosphate Buffered Saline (PBS), pH 7.2 to make up the volume to 159 
1.0 mL and giving a final concentration of 1.25 mg/mL. PBS was prepared with 160 
tablets purchased from Oxoid, UK containing 0.16 M NaCl, 0.003 M KCl, 0.008 M 161 
Na2HPO4 and 0.001 M KH2PO4. Samples were then loaded (0.01 mL) onto a gel after 162 
mixing with SDS sample buffer (×4). Gels were then stained with Instant blue 163 
(Expedeon Ltd, UK) staining to visualize the protein lane.  164 
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Size-exclusion chromatography 165 
For SEC analysis the bevacizumab solution from a freshly open vial and the stored 166 
syringes was diluted with PBS (1.25 mg/mL, 1.0 mL) and transferred to sample vials 167 
in an autosampler which then loaded 950 μL of each sample onto a SEC column, 168 
(HiLoad 16/600 Superdex 200 prep grade column, GE Healthcare Life sciences, UK) 169 
for separation. SECs were conducted in triplicate for each time point for both syringe 170 
and vial samples using a system comprised of a UV detector (Jasco UV-1570, at 280 171 
nm) and HPLC pump (Jasco PU-980 Intelligent). Azur software was used to process 172 
chromatographic data. 173 
Dynamic light scattering 174 
Malvern Zetasizer Nano-ZS, UK with 633 nm laser source was used for measuring 175 
hydrodynamic diameter of bevacizumab. Contaminating particles such as dust in a 176 
solution can be detected in DLS and cause interference. Hence, bevacizumab solution 177 
from vial and syringe was diluted with 0.22 µm filtered PBS to make 1.25 mg/mL 178 
solution. These were then subjected to measurement by DLS in 1.0 mL disposable 179 
polystyrene cuvettes. Nano-ZS analysis software was used to analyze the 180 
measurements. Each measurement was an average of 25 runs of 10 seconds each, 181 
carried out in duplicate. DLS analysis was performed at time points (T0, T3 and T6) 182 
for the bevacizumab solution obtained from a freshly opened vial and from the 183 
syringe at each time point. Samples from 6 different PC syringes were evaluated at 184 
each time point and three samples were made from the vial. 185 
Active protein concentration using Biacore  186 
Human recombinant VEGF165 (38 kDa MW, purchased from Sigma Aldrich) was 187 
immobilised on a CM5 (534 RU). The high immobilisation level was selected for 188 
concentration assays. The immobilisation was performed using standard carbodiimide 189 
mediated coupling (NHS/EDC, 50/50) and ethanolamine (pH 8.5). Samples were 190 
prepared in HBS-EP running buffer (10 mM HEPES, pH 7.4, 150 mm NaCl, 3.0 mM 191 
EDTA, 0.005% surfactant P20). All binding and concentration measurements were 192 
conducted at 25°C at a flow rate of 10 μL/min. Chip regeneration was accomplished 193 
by exposure to 10.0 mM glycine–HCl (pH 1.5) for 1200 sec. Double-referencing was 194 
performed to account for bulk effects caused by changes in the buffer composition or 195 
nonspecific binding. Data were evaluated with BIAevaluation software (version 2.1) 196 
in Biacore X-100. 197 
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Statistical Analysis 198 
Data was analysed for statistical significance using Student’s t-test and p value of 199 
<0.05 was considered statistically different. Data is presented as mean ± S.D. for at 200 
least triplicate observations. 201 
Results  202 
Gel-electrophoresis (SDS-PAGE) 203 
SDS-PAGE analysis was conducted by diluting bevacizumab solution from a syringe 204 
(PC and PP, 0.05 mL) and the same volume of bevacizumab solution from the vial 205 
(0.05 mL) with PBS buffer (0.95 mL, pH 7.4). Samples (0.01 mL, 1.25 mg/mL) were 206 
analysed by SDS-PAGE (Figure 1A). Three individual samples each from the syringe 207 
and the vial were evaluated. The band at 150 kDa in Figure 1A is the monomer of 208 
bevacizumab. The gels were heavily and equally loaded in an effort to observe any 209 
changes in the presence of higher molecular species (HMWS) of bevacizumab or 210 
degradation products. No change in SDS-PAGE from T0 to T6 was observed for any 211 
of the samples. 212 
FIGURE 1A 213 
Size-exclusion chromatography  214 
Size-exclusion chromatography (SEC) was used in an effort to observe if there was 215 
any aggregation of bevacizumab. Six replicates were obtained for samples stored in 216 
syringes at each time point. Three replicates were obtained at each time point for the 217 
samples obtained directly from freshly opened vials. A representative chromatogram 218 
(Figure 1B) shows the HMWS of bevacizumab at a retention time of 59 min and 219 
monomer at 72 min for bevacizumab stored in the PC syringe for 6 months. Figure 1C 220 
is the area under the curve (AUC) for the HMWS of bevacizumab at different time 221 
points (T0, T3, T6) for PP and PC syringes as compared to the vial. There appeared to 222 
be no significant change in the AUC of this HMWS over the 6-month period for the 223 
PP and PC syringe stored samples as compared to the vial.  224 
FIGURE 1B and C 225 
Dynamic light scattering 226 
On examination with SDS PAGE and SEC, there was no difference in the physical 227 
stability of bevacizumab stored in either polycarbonate (PP) or polypropylene (PC) 228 
syringes. The result obtained for physical stability of bevacizumab fractionated in 229 
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polypropylene syringes was found to be in excellent agreement with a previously 230 
published extensive report.30 Hence, we decided to focus on the polycarbonate 231 
syringes for further analysis as these were used for IVAN study and reports were 232 
submitted to MHRA without published public records.32  233 
The hydrodynamic diameter of bevacizumab stored in PC syringes was found 234 
to be 11.19 with PdI of 0.02 at 25°C (Figure 1D). There was no significant difference 235 
in the size distribution of bevacizumab stored in the syringe after six months of 236 
storage compared to bevacizumab taken fresh from the vial (Figure 1E).  237 
FIGURE 1D and E 238 
Surface plasmon resonance (SPR)  239 
Binding of bevacizumab was evaluated by SPR (Biacore) to calculate the active 240 
concentration of bevacizumab in the syringe compared with the vial. If the binding of 241 
bevacizumab to VEGF decreases due to storage in a syringe, then differences in the 242 
active concentration of bevacizumab from a freshly opened vial should be apparent 243 
when evaluated by SPR.33 The binding of bevacizumab fractionated into PC syringe 244 
was studied during 6-month storage period and compared to bevacizumab in freshly 245 
opened vial.  246 
A CM5 chip was functionalized with VEGF (534 RU) to conduct the binding 247 
assay. The binding study was then performed on bevacizumab that was aliquoted 248 
from a freshly opened vial and from the syringe at each time point. Figure 2A shows a 249 
representative bar chart of the binding for bevacizumab in two concentrations (1.25 250 
and 0.625 mg/mL) from a PC syringe after 6 months storage and from a freshly 251 
opened vial. There did not appear to be any difference in the binding response of 252 
bevacizumab from the syringe at the different time points compared to the 253 
bevacizumab from a freshly opened vial (Figure 2A). For reference, a superposition is 254 
shown in Figure 2B of the sensograms for the bevacizumab from both the vial and the 255 
syringe at the 6 month time point. 256 
FIGURE 2A and B 257 
To calculate the active concentration of bevacizumab from the syringe, a 258 
calibration standard curve was generated with bevacizumab (2.0 – 0.25 mg/mL, 4 259 
dilutions) obtained from a freshly opened vial. Bevacizumab (1.25 mg/mL) from the 260 
PC syringe was prepared from 0.05 mL protein solution into 1.0 mL buffer and was 261 
passed over the CM5 chip to interact with immobilised VEGF. In parallel, 0.05 mL of 262 
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bevacizumab from the vial (1.25 mg/mL) was added to 1.0 mL of buffer and 263 
evaluated. The calibration responses were then used to calculate the active 264 
concentration of bevacizumab in the syringe and vial (Figure 2C). The amount of 265 
bevacizumab in the syringe did not change significantly compared to that observed 266 
for the vial and no difference was observed at T6 compared with T0. 267 
FIGURE 2C  268 
Discussion 269 
There have been previous studies to investigate the physical stability of repackaged 270 
bevacizumab in polypropylene syringes.13, 14, 30 The results from our study suggest 271 
that there is no significant difference in the physical stability of bevacizumab when 272 
repackaged in polycarbonate or polypropylene syringes when compared to 273 
bevacizumab that had been stored in a glass vial. The study was performed at time 274 
points over a six-month period using different techniques.  275 
Bevacizumab is a 150 kDa protein which is displayed as a distinct band 276 
(Figure 1A, Lanes 1-9) by SDS PAGE. There is a faint band seen at about the 260 277 
kDa protein standard band. This may indicate the presence of aggregates of the 278 
antibody, which is also consistent with what was observed by SEC30 (Figure 1B, peak 279 
at 59 min) with the presence of higher molecular weight species. To investigate this 280 
further, fractions were collected from 58-59 min and analysed with SDS-PAGE 281 
(Figure 3) using silver-stain as a detection method. Silver stain is more sensitive than 282 
colloidal blue staining and can detect protein in the range of 5-30 ng.34 Fractions were 283 
also collected at the main peak (71-72 min; Figure 3, Lanes 5-6). The higher 284 
molecular weight band was not observed at the peak of 71-72 min (Figure 3, Lanes 5-285 
6) suggesting that this species was not in equilibrium with bevacizumab. The fractions 286 
obtained from the peak at 58-60 minutes appear to be a heterogeneous population 287 
with bevacizumab HMWS. This higher molecular weight band in SDS-PAGE has 288 
been reported previously13 for bevacizumab in vial and syringe. However, it is 289 
important to note that there is lack of significant difference in the level of HMWS 290 
between vial and PC syringe at different time points between T0 and T6. 291 
FIGURE 3 292 
There was no significant difference in the hydrodynamic radius of 293 
bevacizumab from the vial and the PC syringe over a six-month period when 294 
measured by DLS. A similar result was reported by Paul et al30 for storage stability of 295 
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bevacizumab fractionated in a PP syringe for a period of three months. Paul et al30 296 
also reported that the high molecular weight species (HMWS) present in the 297 
bevacizumab solution in the PP syringe was approximately 360 nm when the DLS 298 
measurement was made at 25°C. However, the hydrodynamic size of the 299 
bevacizumab sample stored at ambient temperature overnight was 100.5 nm (PDI = 300 
0.46) suggesting that the storage temperature has an impact on the bevacizumab 301 
stability profile. 302 
SPR was used to evaluate bevacizumab binding to VEGF and no change in 303 
binding was observed during the 6-month storage period for the bevacizumab stored 304 
in the PC syringes compared to bevacizumab from the vial. SPR is a non-labeling 305 
technique that allows measurement of protein-protein interactions such as antibody-306 
antigen interactions. One of the interacting molecules is immobilised onto a sensor 307 
chip and the other molecule is allowed to flow over the functionalised sensor chip. If 308 
binding occurs between the analyte and immobilised ligand, a measurable response 309 
will be generated. Whereas the BCA assay can be used to determine the total protein 310 
content, SPR and ELISA are used to determine the VEGF binding and active protein 311 
concentration of bevacizumab. Bakri et al33 studied the VEGF binding of 312 
bevacizumab stored in a vial and syringe over six months time using ELISA. In our 313 
study, Biacore was used to study active protein concentration and VEGF binding of 314 
bevacizumab stored in vial and PC syringe for a six month time period. A decrease in 315 
antibody binding will cause a decrease in relative response unit (RU) that is 316 
generated. Biacore is a real time based method and is more sensitive compared to 317 
ELISA while no labelling is required.  318 
Our results using several analytical methods and real time VEGF binding 319 
technique (Biacore) demonstrate that the commercial solution of bevacizumab (25 320 
mg/mL, 16 mL in vial) can be fractionated in polypropylene and polycarbonate 321 
syringes and stored up to 6 months at 40C without any changes in protein physical 322 
stability and VEGF binding of bevacizumab. 323 
 324 
325 
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Summary 326 
What was known before 327 
Previous studies have revealed that repackaged bevacizumab in single use syringe and 328 
ranibizumab have comparable outcome in terms of improvement of visual acuity for 329 
AMD. Different studies on repackaged bevacizumab have been performed to evaluate 330 
physicochemical stability in polypropylene syringe, with shelf storage of up to 3 331 
months. The impact of storage of bevacizumab fractionated into PC polycarbonate 332 
syringe for a longer period of time (6 months) on the quality of VEGF binding and 333 
protein stability has not been determined.  334 
What this study adds 335 
This 6-month study indicates that the quality of bevacizumab repackaged into 336 
prefilled PC polycarbonate syringes is not different from bevacizumab from a freshly 337 
opened vial. As far as can be determined by SPR, the VEGF binding of bevacizumab 338 
in the polycarbonate PC syringe was the same as that for bevacizumab taken from a 339 
freshly opened vial.  340 
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Titles and legends to figures 353 
 354 
Figure 1. A; SDS-PAGE analysis of bevacizumab solution from the syringes (PC and 355 
PP) and vial, at T0, T3 and T6. Novex Bis-Tris 4-12% gels were stained with 356 
colloidal blue. Lane M: Protein standards. Lanes 1, 4, 7; bevacizumab (1.25 mg/ml) 357 
from vial at T0, T3 and T6 respectively. Lanes 2, 5, 8; bevacizumab (1.25 mg/ml) 358 
from PC syringes at T0, T3 and T6 respectively. Lanes 3, 6, 9; bevacizumab (1.25 359 
mg/ml) from PP syringes at T0, T3 and T6 respectively. B; Size exclusion 360 
chromatograms of bevacizumab from the PC syringe. C; Average percentage AUC 361 
for SEC peak at 58-59 minutes for bevacizumab solution from the PP and PC syringes 362 
and vial at T0, T3, T6 (n=3), No significant difference (p > 0.05) between presence of 363 
HMWS in vial and syringe over 6 months of storage. D; Overlay of size distribution 364 
curves for PC syringe and vial after six-month storage, bevacizumab solution from 365 
vial and syringe have a similar size distribution. E; DLS measurements of 366 
bevacizumab from PC syringes and vial at T0, T3 and T6 at 25 °C (p > 0.05). 367 
 368 
Figure 2. A; The representative binding chart for bevacizumab in PC syringe at T6 369 
(N=3) and freshly opened vial at 1.25 and 0.625 mg/mL concentration, B; Binding 370 
sensograms of PC syringe at 1.25 mg/mL at T6 overlaid with bevacizumab from 371 
freshly opened vial, C; Biacore calculation of the active protein concentrations; 372 
bevacizumab obtained from syringes and the vial (N=3) at T0 and T6. 373 
 374 
Figure 3. SDS-PAGE analysis of bevacizumab fractions eluted from SEC. Novex 375 
Bis-Tris 4-12% gels were stained with silver stain. Lane M: Protein standards. Lane 1: 376 
Bevacizumab from vial. Lane 2-4: Bevacizumab fractions at 58-60 minutes from SEC 377 
represent dimer of bevacizumab. Lane 5,6: Bevacizumab fractions at 71-72 minutes 378 
from SEC represent the monomer content. 379 
 380 
 381 
382 
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Tables 383 
 384 
Table 1 385 
Purpose of study Duration of study Syringe material Ref 
Compare quality of repackaged 
bevacizumab from 5 different 
compounding pharmacies in UK 
14 days Polypropylene syringe 13 
Examine the effect of silicon oil 
microdroplets and mishandling on 
protein aggregation level in 
repackaged bevacizumab 
3 months Plastic syringe 
(material not specified) 
14 
High molecular weight aggregates 
in repackaged bevacizumab 
Not specified Plastic syringe 
(material not specified) 
24 
Stability of bevacizumab 
repackaged in 1 mL 
polypropylene syringes for 
intravitreal administration 
3 months Polypropylene syringe 30 
Table 1. Example studies of storage stability of repackaged bevacizumab in syringes.  386 
 387 
 388 
Table 2 389 
Compositions Polycarbonate (PC) Polypropylene (PP) 
Barrel Luer-lock Slip-lock 
Plunger Rod Polypropylene Polypropylene 
Stopper Latex free elastomer Polyisoprene 
Lubricant Silicone Silicone 
Sterilisation Method Gamma irradiation Gamma irradiation 
Supplier B. Braun Medical Inc 
(Cat. No 309628) 
Becton Dickinson 
(Cat. No 9161406V) 
Table 2. Material compositions for Polycarbonate (PC) and Polypropylene (PP) 390 
syringes.  391 
 392 
 393 
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